Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
While both medications contain the same ingredient, they are approved for different purposes
The blend pulls together four peptides KPV, BPC-157, TB-500, and GHK-Cu into a single 80 mg vial that targets several biological pathways at once: inflammation control, angiogenesis, collagen production, and cell migration
Resmetirom, already approved by the FDA for adults with non-cirrhotic MASH and stage F2F3 fibrosis, is ideal for lean or weight-stable patients with progressive fibrogenesis or atherogenic dyslipidemia
Real needle-free GLP-1 exists: the Wegovy oral tablet (oral semaglutide 25 mg, FDA-approved December 2025, 13.6% weight loss in the OASIS 4 trial) and experimental microneedle patches from Daewoong Therapeutics (80% bioavailability in a 70-person Phase 1 study, 2028-2030 market estimate)
US$ 24.83
US$ 21.19
US$ 24.21
US$ 21.15
